Results of Sanofi-aventis (NYSE: SNY)’ PREVAIL (Prevention of VTE after Acute Ischemic Stroke with LMWH Enoxaparin) trial has been published in the April 21st issue of The Lancet.
Clinical data from the said trial revealed that once daily administration of Clexane® / Lovenox® (enoxaparin sodium injection) 40 mg was more effective than 
UnFractionated Heparin (UFH) 5000 IU twice a day for the prevention of VTE (venous thromboembolism) in patients who suffered an acute ischemic stroke.
PREVAIL study showed a significant 43% relative risk reduction in VTE events was observed with Clexane® / Lovenox® vs. UFH for the primary efficacy endpoint, the composite of symptomatic or asymptomatic DVT, symptomatic and/or fatal PE during the treatment period (10.2 % vs. 18.1%; p= 0.0001).
Venous thromboembolism (VTE) is a general term used to describe the formation of a blood clot (thrombus) that blocks a vein – a common complication among individuals who have experienced an acute ischemic stroke (AIS).
Find more details from the full report (a pdf file).
Comment Preview